ReviewTherapeutical strategies for anxiety and anxiety-like disorders using plant-derived natural compounds and plant extracts
Introduction
Anxiety and related disorders are among the most common of mental disorders. The Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) principles arranged the anxiety disorder spectrum into separate groups for the classical anxiety disorders, trauma- and stressor-related disorders, obsessive-compulsive and related disorders, and dissociative disorders. Based on DSM-5, the classical anxiety disorders also include selective mutism and separation anxiety disorder [1]. According to large population-based surveys, up to 33.7% of the population are affected by an anxiety disorder during their lifetime; it has higher prevalence than the lifetime prevalence of mood disorders and substance use disorders [2], [3], [4], [5], [6]. A broad range of mental declines are included in the definition of anxiety or anxiety-like disorders. They are commonly diagnosed using mental questionnaires and by oral interactions with patient. Instrumental tools like magnetic resonance are used to map the focal point of the disease [7]. Neither diagnosis nor therapy is easy, as the sub-conscious and conscious are involved. Understanding the pathophysiology is crucial for accurate diagnosis [8]. Generally, anxiety is a normal human emotion which arises during stress and/or discomfort. However, when left uncontrolled, anxiety can lead to debilitating overwhelming fear. Patients are mentally crippled, expressing a wide variety of symptoms including restlessness, worry, irritability, muscle tension and sleep problems.
Many symptoms are similar to those which occur in depression and anxiety could ultimately lead to depression [9], [10]. But, compared to depression, anxiety disorders are rarely self-diagnosed while depression is often recognized by patients. Recently Coles and co-workers reported that 50% of patients recognized depression while only 20% correctly recognized anxiety [11]. The findings of Sun et al. [12] suggest that anxiety, depression, and helplessness are important correlates of obsessive-compulsive disorders in Chinese adolescents and it is evident that these different mental disorders have several common signs. More than half of patients with an anxiety disorder have multiple anxiety disorders [2], [13], and almost 30% will have three or more comorbid anxiety or related disorders [2]. Anxiety is often associated with substance use and mood disorders [2], [14]. An estimated 52% of patients with bipolar disorder [15], 60% of patients with major depressive disorder [16], and 47% of those with attention deficit hyperactivity disorder [17] will have an anxiety or related a comorbidity. The high frequency of comorbidity must be considered when diagnosing anxiety and related disorders since this can have important implications for diagnosis and treatment [18]. Anxiety disorders associated with other anxiety or depressive disorders are associated with poorer treatment outcomes and greater severity [19], [20], [21], [22], increased functional impairment [20], increased health service use [23], and higher treatment costs [24]. Patients with anxiety disorders have a higher prevalence of hypertension and other cardiovascular conditions, gastrointestinal disease, arthritis, thyroid disease, respiratory disease, migraine headaches, and allergic conditions compared to those without anxiety disorders [25]. Anxiety has a considerable economic impact on society as well, being associated with greater use of health care services [4], [26] and decreased work productivity [26], [27]. Importantly, studies report that about 40% of patients diagnosed with anxiety and related disorder remain untreated [4], [28].
The manifestation of anxiety and anxiety-like disorders involves a coordinated activity of numerous brain signalling pathways involving different neurotransmitters. Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter which is known to counterbalance the action of the excitatory neurotransmitter glutamate. Other neurotransmitters that modulate complex anxiety responses in the amygdala, including serotonin, opioid peptides, endocannabinoids, neuropeptide Y, oxytocin, and corticotrophin-releasing hormone [29]. GABAergic inhibition is essential for maintaining a balance between neuronal excitation and inhibition in the central nervous system (CNS) [29]. Neuronal inhibition by GABA is mediated by two distinct classes of GABA receptors. Ionotropic GABAA receptor is fast-acting ligand-gated chloride channel responsible for rapid inhibition [30]. GABAB receptor is coupled indirectly via G-proteins to either calcium or potassium channels to produce slow and prolonged inhibitory responses which is involved in the processes of myorelaxation [31]. The GABAA receptor is a transmembrane hetero-oligomer with pentameric structure (α1, α2, β1, β2, and γ subunits) located in the neuronal membrane as is showed in Fig. 1. Activation of GABAA receptors causes an immediate and substantial rise in chloride conductance across the cell membrane, which renders the neuron unable to raise an action potential and leads to “phasic” inhibition of the neuron [32], [33]. Preclinical studies demonstrated that the α2 subunit of GABAA receptor is particularly relevant for the manifestation of anxiety [34]. The neural circuits involved in anxiety comprise inhibitory networks of principally GABAergic interneurons. It is supposed that the presence of allosteric sites on the GABAA receptor allows the level of inhibition of the neuron to be regulated with exquisite precision using different classes of anxiolytic and sedative–hypnotic drugs such as benzodiazepines, barbiturates, or neurosteroids. However, these allosteric sites can be modulated also by wide spectrum of plant natural compounds. Consequent changes in the subunit composition and conformation of the GABAA receptor may represent mechanisms whereby the level of neuronal activity may be affected in pathological anxiety states [29].
Anxiety can be controlled by pharmacotherapy and/or psychotherapy. Antianxiety agents (anxiolytics) are used in pharmacotherapy [35], [36], [37]. The commonly recommended pharmacological agents for treatment of different anxiety and related disorders are benzodiazepines (BDZ), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and reversible inhibitors of monoamine oxidase A (RIMAs). BDZ are the first-line pharmacological anxiolytics drugs, and advanced psychoactive medications were developed in the last 45 years. However, their long-term use is impaired by tolerance development and abuse liability [38], [39], [40]. BDZ may be useful as adjunctive therapy early in treatment, particularly for acute anxiety or agitation, to help patients in times of acute crises, or while waiting for onset of adequate efficacy of SSRIs or other antidepressants [18]. Recent clinical outcomes have shown that SSRIs are effective on various anxiety disorders but have a slow onset of action [41], [42], [43], [44], [45]. SSRIs and SNRIs are usually preferred as initial treatments, since they are generally safer and better tolerated than TCAs or MAOIs [18]. Several anticonvulsants and atypical antipsychotics have demonstrated efficacy in some anxiety and related disorders, but for various reasons, including side effects, as well as limited trial data and clinical experience, these agents are generally recommended as adjunctive therapies. The choice of medication should take into consideration the evidence for its efficacy and safety/tolerability for the treatment of the specific anxiety and related disorder, as well as for any comorbid conditions the patient might have, in both acute and long-term use [18]. Although benzodiazepines, SSRIs, SNRIs and other anxiolytics are often effective, it is clear there is a need for rapidly acting, better tolerated medications with a greater and more sustained response. In this regard, there are also neurosteroids that are powerful allosteric modulators of GABAA and glutamate receptors which lack the unwanated side effects of benzodiazepines [46]. Based on findings from a wide range of preclinical and clinical studies, it is proposed that opioid ligands and its receptors are involved in physiological and dysfunctional forms of anxiety [47]. Many neuropeptides are plenteously expressed in specific brain regions which are involved in emotional processing and anxiety behaviours. In this regard, the various neuropeptides represent awaited candidates for new therapeutic ways against anxiety and anxiety-like disorders [48]. Moreover, glutamate-based anxiolytic ligands, which act through decreasing the activity of glutamatergic neurotransmission, may attenuate excitation in the CNS, thus resulting in anxiolysis [49]. Over the last two decades, some of the most promising molecules in pharmacological studies were addressed as prospective substances for development of new anxiolytics. Fig. 2 summarizes the mechanisms of action of prospective molecules with anxiolytic effects, such as Δ9-tetrahydrocannabinol, modulators of metabotropic glutamate receptors and acid-sensing ion channels, and polyamines that are potentially new substances for the treatment of anxiety [50], [51], [52], [53], [54], [55], [56], [57], [58].
Animal models are often used for the evaluation of molecular mechanisms involved in anxiety and for screening and developing novel drugs for new treatment strategies. Animal models of anxiety are based on conflict situations that can generate opposite motivational states induced by approach-avoidance situations. Common animal models of anxiety include the “ethological” tests that evaluate unlearned/unpunished responses (e.g. elevated plus maze, light-dark box, open field, hole-board, forced-swim), on the other hand, models which involve learned/punished responses belong to “conditioned operant conflict tests” (e.g. Vogel conflict test) [59], [60].
The elevated plus maze test is based on the natural aversion of mice for open and elevated areas, as well as on their natural spontaneous exploratory behaviour in novel environments. The apparatus consists of open arms and closed arms, crossed in the middle perpendicularly to each other, and a centre area. Mice are given access to all of the arms and are allowed to move freely between them. The number of entries into the open arms and the time spent in the open arms are used as indices of open space-induced anxiety in mice [61]. The light/dark test is based on the innate aversion of rodents to brightly illuminated areas and on the spontaneous exploratory behaviour of rodents in response to mild stressors, that is, novel environment and light. The test apparatus consists of a small dark safe compartment (one third) and a large illuminated aversive compartment (two thirds) [62]. The open field is an arena with walls to prevent escape. The concept is based on conflicting innate tendencies on the avoidance of bright light and open spaces and of exploring novel environments. The result of these two conflictions is anxiety. Similar hole-board test was designed to mitigate the flaws of the open field test [63]. In another behavioural test, the forced-swim test, rodents are placed in an inescapable transparent tank that is filled with water and their escape related mobility behaviour is measured [64]. A classic protocol of the Vogel conflict test is based on situation where rodents are food or water deprived and then placed in an apparatus while simultaneously exposed to punishment in the shape of a mild shock whenever food or water are retrieved. Anxiety decreases the number of times the animal goes to get food or water. On contrary, anxiolytic drugs increase the number of times animals go up to get food or water, even though the animal will still have been punished [65]. There are many other rodent models to test anxiety disorders, e.g. motor activity, rota-rod, tail suspension, marble-burying, free exploratory, zero-maze, social interaction, supressed feeding latency and isolation-induced aggression.
It is well-documented that traditional medicine based on plant natural compounds is effective in the treatment of anxiety and anxiety-like disorders in humans [66]. Importantly, long-term administration of plant natural compounds is not linked with clinically serious adverse effects in humans. On the other hand, pharmacotherapeutical clinical approaches demonstrated that using several conventional synthetic anxiolytic drugs is associated with several adverse effects. Therefore, the screening of suitable safe medicines from natural sources is a considerable challenge of ongoing research. Thus, the objectives of this review is to summarize the current knowledge about the anxiolytic effects of both plant-derived natural compounds and plant extracts. Moreover, we will describe the biological effects, cellular signalling pathways, and clinical administration of plant natural substances.
Data from the available biomedical literature were reviewed and pooled to evaluate anti-anxiolytic effects of plant natural compounds or plant extracts. Relevant studies published in the literature were retrieved by the use of terms: anxiety; anxiolytic; anti-anxiety; alkaloids; terpenes; flavonoids; phenolic acid; lignans; cinnamates; saponins; plant extract, as either a keyword or MeSH (medical subject heading) term in searches of the PubMed (US National Library of Medicine National Institutes of Health) bibliographic database. To reduce reporting bias; only preclinical or clinical studies that involved commonly used and generally-known natural compounds were reviewed. We excluded studies that were not primarily aimed at thr evaluation of the anxiolytic effects.
Section snippets
Natural compounds
For centuries, plants and plant products were used in medicine. Currently, medicinal plants and their products are used as house remedies. In a 2007 survey by the National Center for Complementary and Alternative Medicine nearly 40% of adults in the United States reported to use complementary and alternative medicine [66].
According to the World Health report, ∼450 million people suffer from brain/mental or behavioural disorders, yet only a fraction undergo treatment. While benzodiazepines and
Plant extracts
Except for isolated phytochemicals, there are a plethora of experimental studies testing whole natural substances or extracts as anxiolytics. “Silexan” is a preparation extracted from Lavandula angustifolia L. flowers (containing 80 mg lavender essential oil in gelatine capsules), which with clinical efficient in anxiety disorders [103], [104], [105], [106]. Using rodent model, Kumar [103] evaluated the anxiolytic effects of intraperitoneally administered “Silexan” at doses of 3, 10, and 30
Conclusion
Anxiety remains a major public health problem which is difficult to treat. The traditional treatments have limitations and the number of users with dependance is increasing. This review highlights the search for new medication to treat anxiety in order to improve conventional therapies. New plant natural compounds or plant extracts are under investigation in order to find a better and safer alternative. Currently, several classes of phytochemicals may be considered as supplements to
Conflict of interest
Authors declare no conflict of interest.
Acknowledgements
This work was supported by project “CENTER OF TRANSLATIONAL MEDICINE”, ITMS: 26220220021, co-funded from EU sources and European Regional Development Fund.
References (140)
- et al.
Anxiety disorders in DSM-5: an overview on changes in structure and content
Nervenarzt
(2014) - et al.
Prevalence severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication
Arch. Gen. Psychiatry
(2005) - et al.
Lifetime prevalence and age of onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative
World. Psychiatry
(2007) - et al.
Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care
Fam. Pract.
(2010) - et al.
Prevalence and incidence studies of anxiety disorders: a systematic review of the literature
Can. J. Psychiatry.
(2006) - et al.
Epidemiology of anxiety disorders in the 21 st century
Dialogues Clin. Neurosci.
(2015) - et al.
Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging
Biol. Psychiatry.
(2015) Feelings what are they & how does the brain make them?
Daedalus
(2015)- et al.
Health care professionals' experience-based understanding of individuals' capacity to work while depressed and anxious
Scand. J. Occup. Ther.
(2015) - et al.
The Diagnostic Apathia Scale predicts the ability to return to work following depression or anxiety
Acta. Neuropsychiatr.
(2014)
Disseminating treatment for anxiety disorders: step 1: Recognizing the problem as a precursor to seeking help
J. Anxiety. Disord.
Correlates of comorbid depression, anxiety and helplessness with obsessive-compulsive disorder in Chinese adolescents
J. Affect. Disord.
Functioning and disability levels in primary care out-patients with one or more anxiety disorders
Psychol. Med.
Depression and anxiety in the United States: findings from the 2006 behavioral risk factor surveillance system
Psychiatr. Serv.
Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics
Can. J. Psychiatry
National comorbidity survey replication, the epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R)
JAMA
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication
Am. J. Psychiatry
Clinical practice guidelines: management of anxiety disorders
Can. J. Psychiatry
Infrequency of pure GAD: impact of psychiatric comorbidity on clinical course
Depress. Anxiety
Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA)
J. Affect. Disord.
Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder
J. Clin. Psychiatry
The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study
J. Affect. Disord.
Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity
Depress. Anxiety
Comorbidities and associated treatment charges in patients with anxiety disorders
Pharmacotherapy
Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions
Arch. Intern. Med.
Generalized anxiety disorder: prevalence, burden, and cost to society
Depress. Anxiety
Disability, employment and work performance among people with ICD-10 anxiety disorders
Aust. N. Z. J. Psychiatry
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection
Ann. Intern. Med.
Anxiety disorders and GABA neurotransmission: a disturbance of modulation
Neuropsychiatr. Dis. Treat.
Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment
Br. J. Pharmacol.
Elucidation of the neural circuits activated by a GABAB receptor positive modulator: relevance to anxiety
Neuropharmacology
GABAA receptors and the diversity in their structure and pharmacology
Adv. Pharmacol.
Toward understanding functional properties and subunit arrangement of α4β2δ γ-Aminobutyric acid, type a (GABAA) receptors
J. Biol. Chem.
Molecular and neuronal substrate for the selective attenuation of anxiety
Science
Long-Term pharmacological treatments of anxiety disorders: an updated systematic review
Curr. Psychiatry Rep.
Preoperative use of anxiolytic-sedative agents; are we on the right track
J. Clin. Anesth.
Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: a randomized clinical trial
J. Consult. Clin. Psychol.
A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder
J. Clin. Psychopharmacol.
Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use
Health. Policy
Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal
Eur. Psychiatry
Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats
Eur. Neuropsychopharmacol.
The adverse skeletal effects of selective serotonin reuptake inhibitors
Eur. Psychiatry
Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: implications for underlying fear circuits
Neuroscience
Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?
Bone
The age- dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review
Prog. Neuropsychopharmacol. Biol. Psychiatry
Neurosteroids as neuromodulators in the treatment of anxiety disorders
Front. Endocrinol. (Lausanne)
Opioids and anxiety
J. Psychopharmacol.
Neuropeptides as therapeutic targets in anxiety disorders
Curr. Pharm.
Glutamate-based anxiolytic ligands in clinical trials
Expert Opin. Investig. Drugs.
Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats
Neuropsychopharmacology
Cited by (34)
Consumption of cashew nut induced anxiolytic-like behavior in dyslipidemic rats consuming a high fat diet
2023, Behavioural Brain ResearchAnxiolytic, antidepressant and antioxidant activity of the methanol extract of Canarium resiniferum leaves
2022, Journal of Traditional and Complementary MedicineCitation Excerpt :Qualitative phytochemical analysis showed that MECR contained a range of structurally-diverse secondary metabolites, including alkaloids, tannins, phenols, and flavonoids. Previous studies have demonstrated that alkaloids, flavonoids, and phenols had anxiolytic activity owing to their high affinity for the benzodiazepine (BZD)-binding site of GABAA receptors.49 Gamma-aminobutyric acid (GABA) is an important inhibitory neurotransmitter in the central nervous system (CNS).
Psychoactive plants and phytochemicals
2021, Phytochemistry, the Military and Health: Phytotoxins and Natural DefensesSemisynthesis of novel magnolol-based Mannich base derivatives that suppress cancer cells via inducing autophagy
2020, European Journal of Medicinal ChemistryAnxiolytic properties of Cymbopogon citratus (DC.) stapf extract, essential oil and its constituents in zebrafish (Danio rerio)
2020, Journal of EthnopharmacologyCitation Excerpt :Interestingly, different classes of phytochemicals present in medicinal plants inhibit the excitatory transmission and promote reduction of anxiety through the benzodiazepine binding (Hanrahan et al., 2011; Johnston et al., 2006). Several studies using medicinal plants as an alternative have shown that crude extracts, essential oils and some isolated compounds isolated from species such as Cymbopogon winterianus Jowitt ex Bor (Poaceae) and Cymbopogon citratus (Blanco et al., 2009; Costa et al., 2011; Leite et al., 2011) interact with CNS and exhibited anxiolytic properties in several animal models of anxiety (Fedotova et al., 2017; Sarris, 2018; Trebatická and Duracková, 2015; Wang et al., 2017). This effect can be related to the high affinity of these natural compounds for the benzodiazepine binding sites of the GABAA receptor (Fedotova et al., 2017; Hanrahan et al., 2011).
- 1
Co-first/equal authorship.